Recently, immune checkpoint inhibitors (ICIs) could reactive the anti-tumor function of T cells by inhibiting the programmed cell death-1 (PD-1) and programmed cell death receptor ligand-1 (PD-L1) pathway [8–10]. The gene discussed is PDCD1; the disease is neoplasm.